ARONIN JEFFREY S
Known title: DirectorCIK: 0001062364
Associated companies
Transaction History
| HRMY | ▲ Buy | Option Exercise | 251,922 | $6.0M | 12/14/2021 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 251,922 | $6.0M | 12/14/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.